OPKO Health (OPK) Scheduled to Post Earnings on Tuesday

OPKO Health (NASDAQ:OPK) is scheduled to be releasing its earnings data after the market closes on Tuesday, May 7th. Analysts expect OPKO Health to post earnings of ($0.09) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

OPKO Health (NASDAQ:OPK) last released its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.09) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.09). The business had revenue of $181.90 million for the quarter, compared to analyst estimates of $177.53 million. OPKO Health had a negative return on equity of 12.69% and a negative net margin of 21.76%. The business’s revenue was down 1.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.11) earnings per share. On average, analysts expect OPKO Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OPKO Health Trading Up 1.2 %

Shares of NASDAQ OPK traded up $0.02 during mid-day trading on Monday, reaching $1.32. 718,679 shares of the company’s stock were exchanged, compared to its average volume of 12,478,317. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.22 and a current ratio of 1.55. The company’s 50-day moving average is $1.13 and its 200-day moving average is $1.22. OPKO Health has a 52-week low of $0.85 and a 52-week high of $2.24.

Insider Buying and Selling at OPKO Health

In related news, CEO Phillip Md Et Al Frost acquired 1,000,000 shares of the firm’s stock in a transaction on Wednesday, February 21st. The shares were acquired at an average cost of $0.99 per share, for a total transaction of $990,000.00. Following the completion of the transaction, the chief executive officer now directly owns 208,368,225 shares in the company, valued at approximately $206,284,542.75. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have acquired a total of 4,600,000 shares of company stock valued at $4,393,000 in the last 90 days. Corporate insiders own 47.26% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on OPK. HC Wainwright reissued a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a report on Wednesday, April 3rd. StockNews.com lowered shares of OPKO Health from a “hold” rating to a “sell” rating in a research report on Friday, March 1st. Barrington Research restated an “outperform” rating and issued a $1.50 target price on shares of OPKO Health in a report on Monday, April 1st. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $5.00 price target on shares of OPKO Health in a research note on Monday, April 1st.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.